Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response kinetics and revaccination timing after anti-SARS-CoV-2 monoclonal antibodies in recovered COVID-19 patients
2022-000905-29Phase 4Active
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tixagevimab + cilgavimab, sotrovimab, tozinameran, elasomeran and NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Effectiveness of revaccination at 4 versus 12 months. Started Mar 2022; status: active.
02
Drugs
tixagevimab + cilgavimabsotrovimabtozinameranelasomeranNVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000905-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000905-29.